Skip to main content
MarketStoryBook

IONS in “The Patent Cliff Sparks a Biotech Land Grab”

Ionis Pharmaceuticals, Inc.

Bull sideFadingExposure: not rated yet

Ionis offers a clinically validated RNA-targeting platform and a growing roster of wholly owned and partnered medicines that can attract licensing capital.

IONS impact map — “The Patent Cliff Sparks a Biotech Land Grab”

How this story travels from the headline to IONS’s own business — positive, negative or mixed, direct or indirect, the mechanism, and how strong the exposure is.

Loading IONS impact map…

Price history, marked with story events

Oct 5, 2026 – Oct 19, 2026 · 11 sessions

Prices updated during market hours · refreshed about every 30 minutes while the market is open · delayed data, not for trading decisions

Numbered markers tie price moves to earnings, trial or study results, management comments and analyst or demand data. Loading events…

Full story

The Patent Cliff Sparks a Biotech Land Grab

Large drugmakers facing revenue holes must buy scarce pipelines, turning clinical validation into strategic currency.

BULL side — Ionis offers a clinically validated RNA-targeting platform and a growing roster of wholly owned and partnered medicines that can attract licensing capital.

Read the full The Patent Cliff Sparks a Biotech Land Grab story